Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Tuesday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) will likely be releasing its results before the market opens on Tuesday, March 31st. Analysts expect Eupraxia Pharmaceuticals to post earnings of ($0.13) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Stock Performance

Eupraxia Pharmaceuticals stock opened at $6.72 on Friday. The stock has a market cap of $241.65 million, a PE ratio of -6.52 and a beta of 1.27. Eupraxia Pharmaceuticals has a fifty-two week low of $2.68 and a fifty-two week high of $9.32. The firm’s 50-day simple moving average is $8.11 and its 200 day simple moving average is $6.96.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Royal Bank of Canada lifted its position in Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after purchasing an additional 59,683 shares during the last quarter. Ingalls & Snyder LLC increased its holdings in shares of Eupraxia Pharmaceuticals by 31.0% in the 4th quarter. Ingalls & Snyder LLC now owns 77,400 shares of the company’s stock worth $584,000 after buying an additional 18,300 shares during the last quarter. UBS Group AG raised its position in shares of Eupraxia Pharmaceuticals by 155.4% during the 3rd quarter. UBS Group AG now owns 95,756 shares of the company’s stock valued at $565,000 after buying an additional 58,257 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Eupraxia Pharmaceuticals by 44.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 58,058 shares of the company’s stock valued at $438,000 after acquiring an additional 17,958 shares during the last quarter. Finally, Cibc World Market Inc. lifted its holdings in shares of Eupraxia Pharmaceuticals by 287.0% in the 4th quarter. Cibc World Market Inc. now owns 58,050 shares of the company’s stock valued at $437,000 after acquiring an additional 43,050 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. William Blair initiated coverage on shares of Eupraxia Pharmaceuticals in a research note on Monday, March 23rd. They issued an “outperform” rating on the stock. Cantor Fitzgerald increased their price objective on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, January 15th. HC Wainwright cut their price objective on Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Finally, Zacks Research downgraded Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.